News for Chemomab Therapeutics Ltd. (CMMB)

TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. ( CMMB) (Chemomab), a clinical stage biotechnology company developing innovativ

**media[481910]**

””Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companieswith ”œKey, Near-Term, Potentially Stock-Moving Catalysts””” TEL

**media[465958]**

**media[451175]**

**media[436944]**

Shares of Recursion Pharmaceuticals, Inc. RXRX dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptom...

Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September...

CMMB stock touches 52-week high at $1.58 amid market fluctuations

France-based semiconductor business Sequans Communications S.A. (SQNS) is up over 146 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

International stocks trading in New York closed higher on Tuesday, as the S&P/BNY Mellon index of American depositary receipts rose 0.2% to 183.67. The European index increased 0.1% to 178.29....

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.

Chemomab Therapeutics Ltd. and its subsidiaries ... | February 21, 2023

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.

Read Alterity Therapeutics (NASDAQ:ATHE) vs. Chemomab Therapeutics (NASDAQ:CMMB) Head to Head Survey at ETF Daily News

Read Chemomab Therapeutics (NASDAQ:CMMB) versus Aeglea BioTherapeutics (NASDAQ:AGLE) Financial Analysis at ETF Daily News

Read Chemomab Therapeutics (NASDAQ:CMMB) Upgraded to “Hold” by Zacks Investment Research at ETF Daily News

Read Zacks: Analysts Expect Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Will Post Earnings of -$0.40 Per Share at ETF Daily News

Read Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Significant Decline in Short Interest at ETF Daily News